share_log

3SBio Inc. (HKG:1530) Interim Results: Here's What Analysts Are Forecasting For This Year

3SBio Inc. (HKG:1530) Interim Results: Here's What Analysts Are Forecasting For This Year

三生制药股份有限公司(HKG:1530)中期业绩:这一年分析师们做出了怎样的预测
Simply Wall St ·  08/24 20:15

It's been a mediocre week for 3SBio Inc. (HKG:1530) shareholders, with the stock dropping 12% to HK$5.73 in the week since its latest half-year results. 3SBio reported CN¥4.4b in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of CN¥0.45 beat expectations, being 2.3% higher than what the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

这对3SBio股东来说是一个平庸的一周,股票在最新半年度业绩公布后的一周下跌了12%,至5.73港元。3SBio报告了44亿人民币的营业收入,与分析师预测基本一致,尽管每股收益(EPS)为0.45港元,超过了预期,比分析师预期高2.3%。分析师通常会在每次财报发布后更新他们的预测,我们可以从他们的预测中判断他们对公司的观点是否发生了变化,或者是否有任何新的问题需要注意。我们已经收集到了最新的法定预测,以了解分析师是否在根据这些业绩更新了他们的盈利模型。

1724544949901
SEHK:1530 Earnings and Revenue Growth August 25th 2024
8月25日2024年香港交易所股票代码为1530的公司盈利和营收增长

Taking into account the latest results, the consensus forecast from 3SBio's eleven analysts is for revenues of CN¥8.81b in 2024. This reflects a credible 4.6% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to expand 10% to CN¥0.78. In the lead-up to this report, the analysts had been modelling revenues of CN¥8.75b and earnings per share (EPS) of CN¥0.77 in 2024. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

考虑到最新的业绩,3SBio的11位分析师的共识预测是2024年营业收入为881亿元人民币。这相对于过去12个月的数据,反映出了4.6%的可靠增长。预计法定每股收益将扩大10%,达到0.78元人民币。在此报告之前,分析师的盈收预测是2024年营收为875亿元人民币,每股收益为0.77元人民币。所以明显可以看出,尽管分析师已经更新了他们的预测,但对业务的预期并没有发生重大变化。

The analysts reconfirmed their price target of HK$8.06, showing that the business is executing well and in line with expectations. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values 3SBio at HK$10.03 per share, while the most bearish prices it at HK$6.22. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

分析师重申了每股目标价港元8.06元的股票价格,表明公司在执行方面表现良好并与预期一致。专注于单一目标价可能不明智,因为共识目标实际上是分析师目标价的平均值。因此,一些投资者喜欢看一下预估范围,以了解对公司的估值是否有任何不同意见。目前,最看好的分析师将3SBio估值为每股10.03港元,而最看淡的分析师将其估值为每股6.22港元。如你所见,分析师对该股未来的看法并不完全一致,但预估范围仍然相对较窄,这可能表明结果并非完全不可预测。

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We can infer from the latest estimates that forecasts expect a continuation of 3SBio'shistorical trends, as the 9.4% annualised revenue growth to the end of 2024 is roughly in line with the 10% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 25% per year. So it's pretty clear that 3SBio is expected to grow slower than similar companies in the same industry.

我们可以从更大的角度来看待这些预测,比如与过去业绩的对比,以及相对于行业其他公司预测的看好程度。从最新预测中我们可以推断出,预计3SBio的历史趋势将得到延续,到2024年底的年化收入增长率9.4%大致与过去五年的10%年度增长率相符。相比之下,我们的数据显示,同行业其他有分析师覆盖的公司预计每年收入增长25%。所以很明显,3SBio预计增长速度将比同行业的其他公司慢。

The Bottom Line

最重要的事情是分析师增加了它对下一年每股亏损的估计。令人欣慰的是,营收预测未发生重大变化,业务仍有望比整个行业增长更快。共识价格目标稳定在28.50美元,最新估计不足以对价格目标产生影响。

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that 3SBio's revenue is expected to perform worse than the wider industry. The consensus price target held steady at HK$8.06, with the latest estimates not enough to have an impact on their price targets.

最重要的一点是,市场情绪没有发生重大变化,分析师们重申该公司的业绩与之前的每股收益预测一致。幸运的是,分析师们也重申了他们对该公司营业收入的预测,表明该公司的表现与预期相符。尽管我们的数据确实显示,3SBio的营业收入预计表现将比整个行业差。市场一致看好的目标价仍然保持在8.06港币,最新的预测对其目标价没有产生影响。

With that in mind, we wouldn't be too quick to come to a conclusion on 3SBio. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple 3SBio analysts - going out to 2026, and you can see them free on our platform here.

在这种情况下,我们不应该过于草率地得出关于3SBio的结论。长期的盈利能力比明年的利润更重要。我们有从多个3SBio分析师那里得到的截至2026年的预测,您可以在我们的平台上免费查看这些预测。

However, before you get too enthused, we've discovered 1 warning sign for 3SBio that you should be aware of.

然而,在你过于兴奋之前,我们发现3SBio存在一个警示信号,你需要知道。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发